Tills Pharm-IT Limited 13752959 false 2023-12-01 2024-11-30 2024-11-30 The principal activity of the company is that of SAS programming and consulting. Digita Accounts Production Advanced 6.30.9574.0 true true 13752959 2023-12-01 2024-11-30 13752959 2024-11-30 13752959 core:CurrentFinancialInstruments 2024-11-30 13752959 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 13752959 1 2024-11-30 13752959 bus:SmallEntities 2023-12-01 2024-11-30 13752959 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 13752959 bus:FilletedAccounts 2023-12-01 2024-11-30 13752959 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-11-30 13752959 bus:RegisteredOffice 2023-12-01 2024-11-30 13752959 bus:Director2 2023-12-01 2024-11-30 13752959 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 13752959 countries:England 2023-12-01 2024-11-30 13752959 1 2023-12-01 2024-11-30 13752959 1 2023-11-30 13752959 2022-12-01 2023-11-30 13752959 2023-11-30 13752959 core:CurrentFinancialInstruments 2023-11-30 13752959 core:CurrentFinancialInstruments core:WithinOneYear 2023-11-30 13752959 1 2023-11-30 13752959 1 2022-12-01 2023-11-30 13752959 1 2022-11-30 iso4217:GBP xbrli:pure

Registration number: 13752959

Tills Pharm-IT Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 November 2024

 

Tills Pharm-IT Limited

Contents

Statement of Financial Position

1

Notes to the Unaudited Financial Statements

2 to 4

 

Tills Pharm-IT Limited

(Registration number: 13752959)
Statement of Financial Position as at 30 November 2024

Note

2024
£

2023
£

Current assets

 

Debtors

4

37,327

-

Cash at bank and in hand

 

34

8,416

 

37,361

8,416

Creditors: Amounts falling due within one year

5

(94,690)

(80,555)

Net liabilities

 

(57,329)

(72,139)

Capital and reserves

 

Called up share capital

1

1

Profit and loss account

(57,330)

(72,140)

Shareholders' deficit

 

(57,329)

(72,139)

For the financial year ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Statement of Comprehensive Income.

Approved and authorised by the director on 28 August 2025
 


M P Njau
Director

 

Tills Pharm-IT Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Petitor House
Nicholson Road
Torquay
Devon
TQ2 7TD

Principal activity

The principal activity of the company is that of SAS programming and consulting.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling which is the functional currency of the entity.

Going concern

The financial statements have been prepared on a going concern basis, on the understanding that the director will continue to financially support the company.

 

Tills Pharm-IT Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024 (continued)

2

Accounting policies (continued)

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities

Financial instruments

Recognition and measurement
A financial asset or a financial liability is recognised only when the company becomes party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Tills Pharm-IT Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024 (continued)

4

Debtors

2024
£

2023
£

Other debtors

37,327

-

37,327

-

5

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

91,342

73,600

Accruals and deferred income

3,348

6,638

Other creditors

-

317

94,690

80,555

6

Reserves

Profit and loss account:

This reserve records retained earnings and accumulated losses.

7

Related party transactions

Transactions with the director

2024

At 1 December 2023
£

Advances to director
£

Repayments by director
£

At 30 November 2024
£

Director

317

(37,327)

(317)

(37,327)

         
       

 

2023

At 1 December 2022
£

Repayments by director
£

At 30 November 2023
£

Director

213

104

317